Evaluation of adjuvant therapy in soft tissue sarcoma. A collaborative multidisciplinary approach

Pinedo, H.M.; Vendrik, C. P. J.; Bramwell, Vivien; Slooten, E. A. van; Deakin, DP; Unnik, J. A. M. van; Staquet, Marie‐Jeanne; Sylvester, Richard; Bonadonna, G.

doi:10.1016/0014-2964(79)90158-0

Cited by 11 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In [24,25]. Whereas adjuvant chemotherapy offered no clinical benefit in progression-free or overall survival by tumor size, grade, or histologic subtype, it appeared to benefit patients with microscopically positive (R1) resections.…”

Section: Neoadjuvant Chemotherapy For High-risk (Stage Ii/iii) Patienmentioning

confidence: 99%

Neoadjuvant treatment of soft‐tissue sarcoma: A multimodality approach

Reynoso

Subbiah

Trent

et al. 2010

Journal of Surgical Oncology

View full text Add to dashboard Cite

Unlike epithelial cancers that are both more homogeneous and easily categorized by their respective tissues of origin (e.g., breast or lung cancer), sarcomas represent a diverse class of molecularly distinct bone and soft-tissue mesenchymal neoplasms of more than 50 subtypes. This diversity, as well as the relative rarity of sarcomas as a whole, has presented challenges in conducting prospective randomized clinical trials to assess the value of neoadjuvant chemotherapy for any given subtype. Most clinical trials and meta-analyses have neglected the phenotypic and molecular heterogeneity differentiating one sarcoma subtype from another in favor of a simplified grouping that ensures timely trial completion. As the success of treating gastrointestinal stromal tumors (GISTs) with imatinib demonstrates, a decision to provide neoadjuvant chemotherapy must take into consideration both the subtype being treated and the effect such treatment would be expected to exert upon that subtype.

show abstract

Section: Neoadjuvant Chemotherapy For High-risk (Stage Ii/iii) Patienmentioning

confidence: 99%

Neoadjuvant treatment of soft‐tissue sarcoma: A multimodality approach

Reynoso

Subbiah

Trent

et al. 2010

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

The Surgical Treatment and Outcome of Soft-Tissue Sarcoma

Abbas¹

1981

Arch Surg

171

View full text Add to dashboard Cite

Adjuvant Chemotherapy of Adult High‐Grade Soft Tissue Sarcoma

Mills

1982

Journal of Surgical Oncology

View full text Add to dashboard Cite

Of 12 adult patients with high-grade soft tissue sarcoma receiving adjuvant chemotherapy and at risk for 36-84 months, 9 (75%) remain metastasis free and 10 (83%) have adequate local disease control with limb preservation. This is significantly better (P greater than 0.015) than a comparable "historic" control of 48 previously treated patients. The results correlate well with the few similar studies reported.

show abstract

Evaluation of adjuvant therapy in soft tissue sarcoma. A collaborative multidisciplinary approach

Cited by 11 publications

References 27 publications

Neoadjuvant treatment of soft‐tissue sarcoma: A multimodality approach

Neoadjuvant treatment of soft‐tissue sarcoma: A multimodality approach

The Surgical Treatment and Outcome of Soft-Tissue Sarcoma

Adjuvant Chemotherapy of Adult High‐Grade Soft Tissue Sarcoma

Contact Info

Product

Resources

About